Piper Sandler reiterates Amneal stock rating on earnings beat
Piper Sandler maintained an Overweight rating and $21.00 price target for Amneal Pharmaceuticals (NYSE: AMRX) after its Q3 earnings beat estimates. Amneal reported $0.26 EPS on $862.7M revenue, raising 2026 revenue guidance to $3.15B-$3.25B. Shares are up 78% year-over-year, trading near a 52-week high. Piper Sandler expects steady EBITDA growth and improved leverage ratios.
How this was made
The 30-second read
Why it matters
The combination of an earnings beat, guidance increase, and a reiterated bullish analyst stance can drive incremental demand for the stock, though valuation concerns may temper follow-through.
Market read
Traders can reassess AMRX’s near-term outlook using the raised 2026 revenue guidance and the reiterated analyst price target, while monitoring valuation risk mentioned in the piece.
What to watch
The article does not quantify margin or cash-flow changes; traders may discount the EBITDA/leverage narrative if working-capital or pipeline execution disappoints.
Background
Amneal reported Q3 2026 adjusted EPS and revenue beats and raised 2026 total revenue guidance; Piper Sandler reiterated an Overweight rating and $21 price target.
Ticker impact
Piper Sandler reiterates Overweight and a $21 PT on Amneal after Q3 results beat EPS and revenue and the company raised 2026 revenue guidance.
Likely upward bias as traders weigh raised 2026 revenue guidance against valuation concerns highlighted in the article.
The article includes a fresh guidance raise (2026 revenue range) plus an analyst reiteration with an explicit PT, both of which can support near-term positioning despite valuation commentary.
Market effects
Supports sentiment for complex generics and biosimilars names by reinforcing demand/visibility narrative.
Limited, primarily affects US small/mid-cap pharma/generics sentiment.
Low, no direct cross-border catalyst beyond general sector read-through.
Counterpoint
Valuation is flagged as rich (P/E cited), so upside may be capped if investors focus on multiple compression risk rather than the guidance raise.
Key entities
- companyAmneal Pharmaceuticals
Subject of the article, with Q3 beat and raised 2026 revenue guidance; rated Overweight by Piper Sandler with a $21 PT.
- analyst_firmPiper Sandler
Reiterated Overweight rating and $21 price target following Amneal’s Q3 results.
